Business
Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic
LA JOLLA, Calif., August 11, 2025--Equillium, Inc. ("Equillium" or the "Company") (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced it has entered into a definitive securities purchase agreement with leading healthcare investors that will provide up to $50 million in gross proceeds to Equillium. The private placement is comprised of (i) an initial upfront financing of approximately $30 million in gross procee
About this update from Abivax Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":8918,"height":3592,"url":"https://media.zenfs.com/en/business-wire.com/b80d18c9009a46d2b5011240a3e86cee"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/phbw9k3.W42zC6MGYOyeZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM4NztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b80d18c9009a46d2b5011240a3e86cee","width":960,"height":387},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Me.NDLKn0cFmyYK0ON5DQA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NjY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/b80d18c9009a46d2b5011240a3e86cee","width":1200,"height":483}},"lazy":false},{"type":"text","content":"Financing led by ADAR1 Capital Management and Janus Henderson Investors","length":71,"tagName":"p","attribs":{}},{"type":"text","content":"$30 million up front with the potential to receive an additional $20 million at clinical study initiation","length":105,"tagName":"p","attribs":{}},{"type":"text","content":"Phase 1 clinical study initiation planned mid-2026; data anticipated approximately 6 months thereafter","length":102,"tagName":"p","attribs":{}},{"type":"text","content":"LA JOLLA, Calif., August 11, 2025--(BUSINESS WIRE)--Equillium, Inc. ("Equillium" or the "Company") (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced it has entered into a definitive securities purchase agreement with leading healthcare investors that will provide up to $50 million in gross proceeds to Equillium. The private placement is comprised of (i) an initial upfront financing of approximately $30 million in gross proceeds in exchange for approximately 52.6 million shares of common stock (or, for certain investors, pre-funded warrants in lieu of common stock), representing a purchase price of $0.57 for each share of common stock sold at the initial closing (or $0.5699 for each pre-funded warrant sold in lieu of common stock at the initial closing), and (ii) the potential for up to an additional $20 million in gross proceeds in exchange for up to approximately 35.1 million shares of common stock (or, for certain investors, pre-funded warrants in lieu of common stock), subject to achieving specified milestones rela...